Related Experiment Videos
Cell cycle effects of gemcitabine.
P Cappella1, D Tomasoni, M Faretta
1Department of Oncology, Istituto di Ricerche Farmacologiche Mario Negri, Milan, Italy.
International Journal of Cancer
|July 4, 2001
Summary
Gemcitabine (dFdC) treatment impacts cancer cell cycle progression, affecting cytotoxicity. The timing of subsequent treatments, including with cisplatin, is crucial for effectiveness, highlighting cell kinetics as a key factor.
Area of Science:
- Molecular Pharmacology
- Cancer Cell Biology
- Chemotherapy
Background:
- Gemcitabine (2',2'-difluoro-2'-deoxycytidine, dFdC) is an anticancer drug with known clinical activity in solid tumors.
- While its biochemical mechanism is studied, the impact of dFdC on cell cycle kinetics and its role in cytotoxicity remain less understood.
- Understanding cell population dynamics is essential for optimizing dFdC treatment strategies, especially in combination therapies.
Purpose of the Study:
- To investigate the role of cell population kinetics in gemcitabine (dFdC) cytotoxicity.
- To clarify how single, repeated, and combination treatments (dFdC with cisplatin) affect cancer cell cycle progression.
- To determine the influence of treatment intervals on the efficacy of sequential dFdC or dFdC-cisplatin therapies.
Main Methods:
- Ovarian cancer cells were treated in vitro with gemcitabine (dFdC) across a range of concentrations (10 nM to 10 microM).
- Cell kinetics were analyzed using DNA-bromodeoxyuridine flow cytometry to assess DNA synthesis inhibition and cell cycle phase distribution (G1, S, G2M).
- Cytotoxicity was evaluated using a sulforhodamine B assay for both single-agent and combination treatments.
Main Results:
- Gemcitabine (dFdC) rapidly inhibited DNA synthesis, but its cytotoxic effect extended beyond S-phase cells.
- Cells experienced a dose-dependent G1 block, followed by delays in G2M and G1 phases upon cell cycle re-entry.
- The efficacy of repeated dFdC or dFdC-cisplatin treatments was significantly influenced by the time interval between administrations.
Conclusions:
- Cell cycle kinetics, including delays and re-entry patterns after gemcitabine (dFdC) exposure, are critical determinants of its cytotoxicity.
- The effectiveness of sequential chemotherapy regimens involving dFdC or dFdC-cisplatin is highly dependent on the scheduling of treatments.
- Optimizing treatment intervals based on cell population dynamics is essential for maximizing the therapeutic benefit of gemcitabine-based chemotherapy.